News Protein from Parasite Lowers Relapse Rates, Evidence of Demyelination in Mice with MS Protein from Parasite Lowers Relapse Rates, Evidence of Demyelination in Mice with MS by Patricia Silva, PhD | December 1, 2016 Share this article: Share article via email Copy article link A moleculeĀ secreted by a parasite was seen to prevent autoimmune reactionsĀ in a mouse model of multiple sclerosis (MS). As this molecule, a protein factor or peptide, also worked to preventĀ diabetes, researchers suggestĀ it might be developed intoĀ aĀ potential treatment for autoimmune diseases. The study, “A parasite-derived 68-mer peptide ameliorates autoimmune disease in murine models of Type 1 diabetes and multiple sclerosis,” was published in the journal Scientific Reports. AĀ link between parasitic infections and autoimmunity is not new. Researchers have reported that in areas where parasitic infections are common, autoimmune diseases are rare. Scientists even suggest that the co-evolution of parasites and humans made the human immune system dependent on parasites. Similar connectionsĀ are known to exist with bacteria, which are increasingly found to be crucial for human health. Earlier studies have even explored if deliberate infection with certain parasites can treat autoimmune disease. Nevertheless, an infection with live parasites has its downsides, oftenĀ resulting inĀ side effects that areĀ difficult to control. Researchers at the University of Technology Sydney, in Australia, suggested that focusing on the specific molecules released by parasites that mediate immune system responses may be a better approach. Previously, researchers isolated two factors secreted by the common liver fluke, or flatworm (the helminth parasiteĀ Fasciola hepatica). Treating mice with a crude mix of all factors secreted by this parasite prevented experimental autoimmune encephalomyelitis (EAE) ā the mouse version of MS. In this study, researchers tested two parasite peptides, called FhHDM-1 and FhCL1, in a mouse model of MS. FhHDM-1 reduced the severity of disease and lowered the number of relapses in EAE mice. Over the 60 days that followedĀ injections of FhHDM-1, half of these mice had only one relapse, compared to two to five relapses in control mice over 70 days after EAE was triggered in them. What’s more, 20 percent of the FhHDM-1 treated mice were completely free of disease.Ā Treated mice also had lower levels of inflammation in the brain, and evidence of fewer neurons having lost their myelin. (Tests Ā done in a model of type 1 diabetes also showed positive results.) In contrast, the other peptide, FhCL1, did not improve disease symptoms or slow its progression in the mice. Earlier studies suggested that the parasite peptide switched the type of immune response from one governed by Th1-cells (pro-inflamatory) to one governed by a protective Th2-cell (anti-inflammatory). Th1-cells, along with Th17-cells and the immune mediators they secrete, are believed to drive autoimmune reactions. Researchers did not find evidence that the treatment suppressed Th1-cells or boosted Th2-cell responses. Instead, they noted that the treatment suppressed the reactions of macrophages, which secreted lower levels of the cytokines TNF and IL-6 than was seen in untreated control cells. In a final test of the peptide’s potential as a treatment in patients, the team tested the ability of FhHDM-1 to block the actions of human macrophages. They demonstrated that the factor blocked the production of TNF and IL-6, both in isolated macrophages and in samples of human blood. “This study provides proof-of-concept in two pre-clinical rodent models that a single parasite-derived peptide offers a novel treatment for individuals predisposed to, or suffering from, autoimmune disease,” the researchers concluded. “The ability of FhHDM-1 to modulate macrophage function, combined with its efficacy in disease prevention in multiple models, suggests that FhHDM-1 has considerable potential as a treatment for autoimmune diseases.” Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags autoimmune disease, diabetes, EAE, experimental autoimmune encephalomyelitis, macrophages
April 23, 2024 News by Mary Chapman Itās year 10 for MSAAās upcoming Improving Lives Benefit for MS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada